Evidence-Based Complementary and Alternative Medicine

Review Article

A Systematic Review of Xuezhikang, an Extract from Red Yeast Rice, for Coronary Heart Disease Complicated by Dyslipidemia

Table 3

Analysis of clinical events.


Outcomes (comparisons)	Treatment group (n/N)	Control group (n/N)	RR	95% CI

(1) All-cause mortality
Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]	126/2429	189/2441	0.67
(2) Mortality of CHD
(2.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]		134/2441	0.69
(2.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Guan 2010 [22]		6/64	0.15
Lou et al. 2008 [28]		1/41	0.95
	Overall (FEM, I² = 13%)		0.26
(2.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]			0.33
(2.4) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32]			0.15
(3) Myocardial infarction
(3.1) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]			0.39
(3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al. 2008 [28]			0.95
(3.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]			0.2
(4) Revascularization
(4.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]			0.67
(4.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al. 2008 [28]			1.14
(5) Rehospitalization
(5.1) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al 2008 [28]			1.02
(5.2) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]			0.2